


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated, purified or synthetic compound selected from the group consisting of pPomolic acid, its isomers of pomolic acid and derivatives thereof, wherein the compound is effective to treat~~characterized by their use in the treatment of~~ multidrug resistant tumours, ~~with the structure (I):~~



2. (Currently Amended) A pPharmaceutical composition for the treatment of treating multidrug resistant tumour~~tumors~~, said composition comprising an effective amount of at least one compound of~~characterized by the fact of containing a sufficient amount of pomolic acid, its isomers or derivatives in accordance with claim 1 and at least one pharmaceutically acceptable vehicle~~~~pharmaceutical accepted vehieles.~~

3. (Currently Amended) The pPharmaceutical composition, in accordance with claim 2,~~characterized by the fact that~~wherein the at least one pharmaceutically acceptable vehicle should be~~is~~ acceptable for systemic or oral administration.

4. (Currently Amended) The pPharmaceutical composition, in accordance with claim 2, ~~characterized by the fact that~~wherein the at least one pharmaceutically acceptable ~~accepted~~ vehicle is an organic solvent, further diluted in a saline solution or another equivalent isotonic solution.

5. (Currently Amended) The pPharmaceutical composition, in accordance with claim 4, ~~characterized by the fact of~~wherein the organic solvent ~~be~~is dimethylsulfoxide or another organic solvent acceptable to be used in humans, diluted in a saline solution.

6. (Currently Amended) The pPharmaceutical composition, in accordance with claim 2, ~~characterized by the~~wherein a concentration of the compound~~pomolic acid, its isomers and/or derivatives, being utilized between~~is from 0.1% and to 100% in weight/volume.

7. (Currently Amended) The pPharmaceutical composition, in accordance with claim 6, ~~characterized by the fact that~~wherein the concentration of ~~pomolic acid, its isomers and/or derivatives, being utilized~~is 10mg/ml to 1000 mg/ml.

8. (Currently Amended) A mMethod to prepare the a pharmaceutical composition for the treatment of~~treating~~ multidrug resistant tumors, said method comprising solubilizing at least one compound selected from the group consisting of~~characterized by having a first step for the solubilization of pomolic acid, its isomers of pomolic acid and/or derivatives thereof, in dimethylsulfoxide or another~~a pharmaceutically acceptable solvent for human use, followed by dilution in saline solution, in such a way that the a concentration of dimethylsulfoxide the pharmaceutically acceptable solvent does not exceed 1%.

9. (Currently Amended) The mMethod to prepare the pharmaceutical composition, in accordance with claim 8, ~~characterized by the fact that the~~wherein a concentration of the at least one compound is~~pomolic acid, its isomers and/or derivatives utilized in the first step of solubilization being 10mg/ml to 1000 mg/ml.~~

10. (Currently Amended) A mMethod for the treatment of multidrug resistance tumourtumors characterized by thecomprising administration of a therapeutically efficacious amount of at least one compound selected from the group consisting of pomolic acid, its isomers of pomolic acid and/or derivatives thereof.

11. (Currently Amended) The mMethod for treatment; in accordance with claim 10, characterized bywherein the administration of a therapeutically efficacious amount of pomolie acid, its isomers and/or derivatives is systemic or oral.

12. (Currently Amended) The mMethod for treatment; in accordance with claim 11, characterized bywherein the therapeutically efficacious amount of pomolie acid, its isomers and/or derivatives, being betweenis from 0.01mg/kg and to 100mg/kg body weight.

13. (Canceled).

14. (Canceled).